A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge.

Autor:	Wuertz KM; U.S. Military HIV Research Program, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Barkei EK; Veterinary Pathology Division, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Chen WH; Emerging Infectious Diseases Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Martinez EJ; Emerging Infectious Diseases Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Lakhal-Naouar I; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.; Diagnostics Countermeasures Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Jagodzinski LL; Diagnostics Countermeasures Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Paquin-Proulx D; U.S. Military HIV Research Program, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Gromowski GD; Virus Diseases Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Swafford I; U.S. Military HIV Research Program, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Ganesh A; U.S. Military HIV Research Program, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Oak Ridge Institute of Science and Education, Oak Ridge, TN, USA., Dong M; U.S. Military HIV Research Program, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Zeng X; Pathology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA., Thomas PV; Emerging Infectious Diseases Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Sankhala RS; Emerging Infectious Diseases Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Hajduczki A; Emerging Infectious Diseases Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Peterson CE; Emerging Infectious Diseases Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Kuklis C; Virus Diseases Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Soman S; Virus Diseases Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Wieczorek L; U.S. Military HIV Research Program, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Zemil M; U.S. Military HIV Research Program, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Anderson A; Emerging Infectious Diseases Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Oak Ridge Institute of Science and Education, Oak Ridge, TN, USA., Darden J; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.; Diagnostics Countermeasures Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Hernandez H; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.; Diagnostics Countermeasures Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Grove H; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.; Diagnostics Countermeasures Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Dussupt V; U.S. Military HIV Research Program, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Hack H; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.; Diagnostics Countermeasures Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA., de la Barrera R; Pilot Bioproduction Facility, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Zarling S; Pilot Bioproduction Facility, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Wood JF; Pilot Bioproduction Facility, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Froude JW; Pilot Bioproduction Facility, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Gagne M; Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Henry AR; Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Mokhtari EB; Virus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Mudvari P; Virus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Krebs SJ; U.S. Military HIV Research Program, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Pekosz AS; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Currier JR; Virus Diseases Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Kar S; BioQual, Inc., Rockville, MD, USA., Porto M; BioQual, Inc., Rockville, MD, USA., Winn A; BioQual, Inc., Rockville, MD, USA., Radzyminski K; BioQual, Inc., Rockville, MD, USA., Lewis MG; BioQual, Inc., Rockville, MD, USA., Vasan S; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Suthar M; Emory Vaccine Center, Department of Pediatrics, Emory School of Medicine, Atlanta, GA, USA., Polonis VR; U.S. Military HIV Research Program, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Matyas GR; U.S. Military HIV Research Program, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Boritz EA; Virus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Douek DC; Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Seder RA; Cellular Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Daye SP; One Health Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Rao M; U.S. Military HIV Research Program, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Peel SA; Diagnostics Countermeasures Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Joyce MG; Emerging Infectious Diseases Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Bolton DL; U.S. Military HIV Research Program, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Michael NL; Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA. nelson.l.michael2.civ@mail.mil., Modjarrad K; Emerging Infectious Diseases Branch, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA. kayvon.modjarrad.civ@mail.mil.
Jazyk:	angličtina
Zdroj:	NPJ vaccines [NPJ Vaccines] 2021 Oct 28; Vol. 6 (1), pp. 129. Date of Electronic Publication: 2021 Oct 28.
DOI:	10.1038/s41541-021-00392-7
Abstrakt:	The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the Alpha (B.1.1.7), and Beta (B.1.351) VOCs in Syrian golden hamsters. SpFN-ALFQ was administered as either single or double-vaccination (0 and 4 week) regimens, using a high (10 μg) or low (0.2 μg) dose. Animals were intranasally challenged at week 11. Binding antibody responses were comparable between high- and low-dose groups. Neutralizing antibody titers were equivalent against WA1, B.1.1.7, and B.1.351 variants following two high dose vaccinations. Dose-dependent SpFN-ALFQ vaccination protected against SARS-CoV-2-induced disease and viral replication following intranasal B.1.1.7 or B.1.351 challenge, as evidenced by reduced weight loss, lung pathology, and lung and nasal turbinate viral burden. These data support the development of SpFN-ALFQ as a broadly protective, next-generation SARS-CoV-2 vaccine. (© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu